Bayer Healthcare LLC

Bayer Healthcare LLC, operating through its Bayer Radiology division and doing business as Bayer, sells MEDRAD injection systems, radiology equipment maintenance services, imaging informatics software, and related medical imaging supplies to federal healthcare agencies as a prime contractor competing in full-and-open procurements with no set-aside participation. A large for-profit pharmaceutical and medical device manufacturer headquartered in Whippany, New Jersey, Bayer competes entirely as a large business across all 1,126 recent prime awards, with zero subcontract activity. The company specializes in contrast media injectors and injection systems for computed tomography, magnetic resonance imaging, and positron emission tomography applications, along with preventative maintenance, emergency repairs, software upgrades, and comprehensive service agreements designed to maintain operational uptime of critical diagnostic imaging infrastructure.

Customer concentration is heavily weighted toward the Department of Veterans Affairs, which accounts for the majority of Bayer's federal business across its distributed Veterans Integrated Service Networks. The top five VISN customers by award count (VA VISN 4, 10, 9, 19, and 5) represent 31 percent of all recent awards. By potential value, VA VISN 19 leads at $13.3 million across 55 awards, followed by VISN 23 at $4.6 million across 30 awards and VISN 10 at $4.3 million across 77 awards—creating a pattern of many smaller orders concentrated in the VA system rather than larger contract vehicles anchoring the portfolio. Beyond the VA, Bayer holds awards with the Defense Health Agency, National Institutes of Health (including the NIH Clinical Center), Indian Health Service, and a small number of Department of Defense field commands. The 40 distinct customer agencies served understate the concentration: the top five VISN units alone represent 31 percent of all awards, and the VA system collectively dominates the footprint.

Bayer's vehicle posture centers on single-award indefinite delivery contracts and blanket purchase agreements within the VA system. The largest parent vehicle by task-order count is Indefinite Delivery Contract VA797P0257 (102 task orders, $14.6 million combined potential value), followed by Blanket Purchase Agreement V552PBPA0629 (60 task orders, $2.9 million). Bayer also holds position on IDCs VA25814D0050 (21 task orders, $536 thousand) and 36C24422D0173 (20 task orders, $464 thousand), as well as additional single-award BPA and IDC vehicles across other VA regional networks. These are not government-wide or multi-award vehicles; they are VISN-specific or facility-specific sole-source vehicles, reflecting Bayer's status as the original equipment manufacturer for the proprietary MEDRAD systems the VA operates. Recent examples include a September 2025 $462.9 million BPA ceiling with VA VISN 4 for MEDRAD sterilizer and injector maintenance across nine medical centers (six BPA calls totaling $166.8 thousand issued the same day), and a September 2022 $418.1 million IDC with VA VISN 4 running through September 2025, authorizing annual delivery orders between $10 thousand and $65 thousand. These vehicles are non-competitive sole-source awards under FAR 6.302-1, reflecting Bayer's monopoly position as the OEM.

Award categories are weighted heavily toward maintenance and repair services. The top NAICS code is Other Electronic and Precision Equipment Repair and Maintenance (328 awards), followed by Surgical and Medical Instrument Manufacturing (283 awards) and Medical, Dental, and Hospital Equipment Merchant Wholesalers (122 awards). The top PSC is Maintenance, Repair, and Rebuild of Medical, Dental, and Veterinary Equipment (409 awards), underscoring that Bayer's federal footprint is driven by ongoing service contracts rather than one-time equipment sales. Recent concrete awards illustrate the work: a November 2026 $48.6 thousand purchase order from VA VISN 2 for MEDRAD injector service maintenance at Syracuse VA Medical Center (preventative maintenance, inspection, calibration, part replacements, onsite service, 90-day warranty, ultimate completion October 2028); an August 2026 $111.9 thousand purchase order from VA VISN 9 for Bayer injector services in Mountain Home, Tennessee (ultimate completion July 2030); a February 2025 $150.4 thousand definitive contract from VA VISN 5 for contrast injectors in Baltimore (ultimate completion February 2029); and recurring syringe-kit orders from the NIH Clinical Center valued at approximately $14.1 thousand per order, issued multiple times per year.

Activity has declined modestly over the past five years: 41 awards in 2022, down to 24 in 2024, with a slight uptick to 27 in 2025. Only three awards appear in 2026 to date, consistent with a mid-year snapshot. The recompete cliff window (next 24 months) shows 27 awards with ultimate completion dates approaching, carrying $1.7 million in combined potential value—a relatively modest recompete exposure given the 1,126-award base and suggests that much of Bayer's portfolio consists of long-term service agreements already in place. Obligated dollars total $76.8 million (81 percent of combined potential value), indicating that most awards are substantially funded. Combined potential value across all awards is $94.6 million, making Bayer a mid-sized federal vendor within the medical equipment maintenance and imaging supplies space, with concentrated exposure to VA sole-source relationships that insulate the vendor from full-and-open competition but expose it to customer consolidation or technology transition risk.